CCIA
PRVB

Campbell & Co Investment Adviser’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Campbell & Co Investment Adviser’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,920
Closed -$137K – 1088
2022
Q4 		$137K Buy
+12,920
New +$104K 0.03% 722

Other funds holding PRVB

SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Campbell & Co Investment Adviser's PRVB Position: Q1 2023 in Review

Campbell & Co Investment Adviser sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2023, closing a stake of 12,920 shares — an estimated $137K sold.

Campbell & Co Investment Adviser first reported a position in PRVB in Q4 2022 and held it in 1 quarter. The position peaked at $137K in Q4 2022. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.

  • Campbell & Co Investment Adviser reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 12,920 Provention Bio, Inc. Common Stock shares in Q1 2023, an estimated $137K.
  • Campbell & Co Investment Adviser first reported a position in Provention Bio, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Provention Bio, Inc. Common Stock position peaked at $137K in Q4 2022.
  • 182 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2023.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2023, filed 11 May 2023.